Your session is about to expire
← Back to Search
Triapine for Uterine Cancer
Study Summary
This trial is testing the anti-cancer drug triapine in women with uterine cancer. It will use markers from tissue samples to see if the drug stops the growth of tumor cells.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have any unmanaged ongoing illnesses.I have not had any previous cancer treatment for endometrial cancer.I have recovered from side effects of previous cancer treatments, except for hair loss.My cancer is a specific type of uterine cancer called serous adenocarcinoma.I can take care of myself but might not be able to do heavy physical work.My heart function is classified as class 2B or better according to NYHA.I can understand and am willing to sign the consent form.I can provide recent tumor tissue or am willing to have a biopsy.I haven't had chemotherapy or radiotherapy in the last 4 to 6 weeks.I have another cancer, but it won't affect this trial's treatment.I do not have G6PD deficiency.I am 18 years old or older.I had hepatitis C but am cured, or I'm being treated with no detectable virus.I am not taking any drugs that interact with Triapine or cause methemoglobinemia.I am scheduled for a surgical removal of the uterus and staging.My kidney function is within the safe range for the trial.I am HIV positive, on treatment, and my viral load is undetectable.I have brain metastases and cannot undergo surgery.I can provide recent tissue samples or am willing to undergo a biopsy for the study.My hepatitis B is under control with treatment.My tumor is large enough for both research and clinical tests.
- Group 1: Treatment (triapine, surgical resection)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the current participation levels of this investigation?
"Affirmative. Information on clinicaltrials.gov suggests that this research study, initially published on November 11th 2020, is still recruiting volunteers. 12 individuals are needed from 6 different medical facilities to complete the trial."
What is the geographic distribution of sites participating in this trial?
"Six medical centres in total are participating in the trial, including University of Miami Miller School of Medicine-Sylvester Cancer Center, UM Sylvester Comprehensive Cancer Center at Deerfield Beach and UM Sylvester Comprehensive Cancer Center at Plantation. Additionally, other three sites can be found throughout the country."
Is there still room for participation in this research endeavor?
"Indeed, the clinicaltrials.gov database conveys that this experiment is presently recruiting participants. It was initially publicized on November 11th 2020 and its entry was last revised on November 30th 2022. A total of 12 individuals from 6 distinct sites need to be recruited for it."
Share this study with friends
Copy Link
Messenger